Madrigal Pharmaceuticals (MDGL) PT Raised to $390 at TD Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MDGL Hot Sheet
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 26 | New: 2
Join SI Premium – FREE
TD Cowen analyst Ritu Baral raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $390.00 (from $349.00) while maintaining an Outperform rating.
The analyst commented, "FDA approved THR-β agonist Rezdiffra (resmetirom) for NASH with moderate to advanced fibrosis 'consistent with F2/F3,' with no biopsy requirement in indication language. The label is very clean with no market-limiting warnings, monitoring requirements or contraindications. A $47.4K WAC was announced, with specialty distribution. We model FY24 sales of $97M and peak sales of $4.9B in 2031."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Joby Aviation Inc (JOBY) PT Lowered to $10 at Needham
- Uber Inc. (UBER) PT Lowered to $100 at Needham
- Qualcomm (QCOM) PT Lowered to $165 at Susquehanna
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Cowen & Co, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
